|
 Kisqali plus the hormone therapy fulvestrant, when compared to
fulvestrant alone, demonstrated a significant improvement in
survival with a 28% reduction in risk of death, Novartis said at the
European Society for Medical Oncology meeting in Barcelona.
Novartis said Kisqali is now the only drug of its kind to show
positive overall survival in two pivotal studies.
The Basel-based firm said this year that Kisqali also boosted
survival for women before menopause with hormone receptor positive,
human epidermal growth factor receptor-2 negative (HR+/HER2-)
advanced or metastatic breast cancer.
"These results arm oncologists with more evidence to make a
confident treatment choice for their hormone receptor-positive
metastatic breast cancer patients," Dennis Slamon, a doctor at the
University of California, Los Angeles Jonsson Comprehensive Cancer
Center involved with the study, said in a statement.
[to top of second column] |
Kisqali had $235 million in sales in 2018, well behind $4.1 billion
for Ibrance, as Pfizer's first-to-market drug captured the lion's
share of women with metastatic HR+/HER2- cancer.
However, a Refinitiv poll found analysts expect Kisqali, priced at
about $130,000 per year, to have sales of about $1.2 billion
annually by 2024.
(Reporting by John Miller; Editing by Alexander Smith)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
